May 23, 2022 / 08:30PM GMT
Operator
Greetings. Welcome to the Windtree Therapeutics Corporate Update Call. (Operator Instructions) And please note that this conference is being recorded.
I will now turn the conference over to John Hamill, CFO of Windtree Therapeutics. Thank you, sir. You may begin.
John P. Hamill - Windtree Therapeutics, Inc. - Senior VP, CFO, Treasurer & Corporate Secretary
Thank you, operator, and thank you all for joining the Windtree management team today.
On today's call are Craig Fraser, our President and Chief Executive Officer; Steve Simonson, our Chief Medical Officer; and Eric Curtis, our Chief Operating Officer.
We previously announced the positive topline result from the SEISMiC Phase II study in early cardiogenic shock, and that further details were under embargo due to the acceptance of the late-breaker at the European Society of Cardiology Heart Failure meeting. That late-breaker presentation occurred earlier today, and we also issued a news release sharing those more detailed results from our study.
Please note that
Windtree Therapeutics Inc to Discuss its Istaroxime Phase 2 Study Call Transcript
May 24, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers